Shahzaib Nabi, MD
Internal Medicine · Aurora, CONPI 1063755072
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $6,460 of the $9,675 with a category attached, or 66.8%. Dova Pharmaceuticals accounts for 69.6% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2021 at $6,398 and has fallen 64.8% since, to $2,254 in 2023. Among internal medicine clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 43 payments — averaging $225.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dova Pharmaceuticals$7K
- Johnson & Johnson$1K
- Janssen Scientific Affairs, LLC$818
- Novartis$174
- E.r. Squibb & Sons, L.L.C.$121
- Global Blood Therapeutics, Inc.$94
- plus $312 from 9 others
What the payments were for
- Consulting fees$2,18023%
- Speaking & faculty fees$6,46067%
- Food & beverage$96110%
- Education$741%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dova Pharmaceuticals | 6 | $6,733 |
| Johnson & Johnson | 3 | $1,423 |
| Janssen Scientific Affairs, LLC | 1 | $818 |
| Novartis | 9 | $174 |
| E.r. Squibb & Sons, L.L.C. | 6 | $121 |
| Global Blood Therapeutics, Inc. | 5 | $94 |
| AstraZeneca | 1 | $74 |
| Gilead | 4 | $69 |
| Sanofi | 1 | $59 |
| Seagen Inc. | 2 | $41 |
| Pfizer | 1 | $16 |
| Pharmacosmos Therapeutics Inc. | 1 | $15 |
| Heron Therapeutics, Inc. | 1 | $13 |
| Kyowa Kirin, Inc. | 1 | $13 |
| Astellas Pharma US Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$9,675 in reported general payments places this provider in the 95th percentile of 1,430 internal medicine providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TavalisseFostamatinib Disodium | 30 | $446,315 |
| RevlimidLenalidomide | 26 | $428,617 |
| IbrancePalbociclib | 27 | $422,541 |
| VerzenioAbemaciclib | 25 | $371,942 |
| XtandiEnzalutamide | 24 | $333,499 |
| LenvimaLenvatinib Mesylate | 12 | $294,311 |
| PomalystPomalidomide | 13 | $281,597 |
| ZejulaNiraparib Tosylate | 13 | $243,008 |
| ImbruvicaIbrutinib | 13 | $207,107 |
| LynparzaOlaparib | 17 | $197,050 |
| Abiraterone Acetate | 61 | $167,632 |
| Lenalidomide | 13 | $150,620 |
| Lupron DepotLeuprolide Acetate | 22 | $122,967 |
| EliquisApixaban | 139 | $88,387 |
| Neulasta OnproPegfilgrastim | 11 | $67,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerIbrance, Eliquis | $16 | $510,928166 claims |
| Astellas Pharma US IncXtandi | $12 | $333,49924 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $121 | $281,59713 claims |
| AstraZenecaLynparza | $74 | $197,05017 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $818 | $167,63261 claims |
| Johnson & JohnsonXarelto | $1,423 | $53,59665 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,430 internal medicine providers in Colorado.
Other internal medicine in Aurora
- Kristine KuhnAurora$61K
- Paul Menard-KatcherAurora$32K
- Cherry DelosreyesAurora$15K
- Shabana JiwaniAurora$10K
- Mauricio WaintrubAurora$9K
- Javier WaksmanAurora$7K
- Kelsey FlintAurora$6K
- Gilad GordonBoulder$476K
- Kathryn PolovitzParker$403K
- Monica GrafalsAvon$401K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.